ClinicalTrials.gg
CompletedNCT03868514PRO-PocketUpdated Nov 18, 2023

Post Market Clinical Follow Up to "Patient Reported Outcome" Using a Titanised Polypropylene Mesh (TiLOOP® Bra Pocket)

An observational study in Breast Reconstruction After Mastectomy, Breast Neoplasm and Breast Cancer, sponsored by pfm medical gmbh. Completed at 12 sites in 2 countries. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by pfm medical gmbh · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
313
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 678 studies in Breast Neoplasms with a site in Germany — 114 open to participants now, 196 under way, 81 of them phase 3. Breast Neoplasms · Germany.

Enrollment
62nd of 92
313 · median 580
Started
2019
with 25 others
Observational
93 of 678
23 open now
Registered
443rd of 678
by date

Among the 678 studies in Breast Neoplasms with a site in Germany, this one is the 62nd largest by enrollment of the 92 observational ones that give a count, is one of 26 that started in 2019, is one of 93 observational ones, and was the 443rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

114 of the 678 studies in Breast Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

109 more — sign in →

All 114 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 678 studies in Breast Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

"PRO-Pocket" - International prospective multicentre Post Market Clinical Follow Up to "Patient reported outcome" in primary or secondary breast reconstruction after mastectomy using a titanised polypropylene mesh (TiLOOP® Bra Pocket)

Read the detailed description

This international, multicentre, non-randomised, observational clinical device investigation will be performed to obtain post market information on TiLOOP® Bra Pocket surgical meshes for a period of up to two years. In particular, on patient reported satisfaction (BreastQTM), cosmetic outcome and the rate of complications.

The objective of the clinical Investigation is to establish the efficacy and safety of the TiLOOP® Bra Pocket.

The Investigation will be performed in ten clinical centres in Germany and Austria.

03

Conditions studied

  • Breast Reconstruction After Mastectomy
  • Breast Neoplasm
  • Breast Cancer
  • Breast Diseases

Keywords

  • breast reconstruction
  • surgical mesh
  • synthetic mesh
  • patient reported outcome
  • breast cancer
  • mesh
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Women with indicated implant based breast reconstruction after mastectomy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age [≥ 18]

Indications of breast reconstruction: confirmed breast cancer, precancerous lesions (DCIS, LCIS), mutation carrier with increased breast cancer risk, strong family history (lifetime risk > 15%)

The patient is capable to realise the nature, aims and possible consequences of the clinical trial (MPG §20.2.1)

Patient information has been provided and all written consents of the patient are available

Exclusion criteria

Exclusion Criteria:

breast cancer

Patient with known against mesh-assisted or plastic-reconstructive breast surgery according to the instruction for use

Patient is kept in an institution under judicial or official orders (MPG §20.3)

Participate in another operative clinical trial, if it relates to the area of reconstructive breast surgery and/or influences the primary endpoint of the clinical trial

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
313 participants (actual)
Patient registry
No

Groups and cohorts

  • TiLOOP Bra Pocket

    Medical Device

    Device: TiLOOP® Bra Pocket

Interventions

  • DeviceTiLOOP® Bra Pocket

    Primary or secondary breast reconstruction following mastectomy with titanised polypropylene mesh TiLOOP® Bra Pocket

06

What researchers measure

Primary outcomes

  1. Quality of Life - Patient reported outcome

    The primary endpoint is defined as the change of the four BreastQ domain scores before study treatment compared to twelve months after study treatment. The BreastQ questionnaire yields a domain score in the range from zero to 100. Wheras a score of 100 is the best score. The study hypothesis is that the patient's QoL after the study intervention treatment is not worse than the QoL prior to the intervention study treatment . The following four domains are relavant: Satisfaction with breasts, Psychosocial well-being, Physical well-being:chest and Sexual well-being.

    Time frame: 12 months after study treatment

Secondary outcomes

  1. Quality of Life - Patient reported outcome

    The change of the four BreastQ domain scores before study treatment compared to six months and 24 months after study treamtment.

    Time frame: 6 and 24 months after study treatment

  2. Complication rate

    The number and rate of occurrence of adverse events is reported as a secondary endpoint along with a tabulation of the types of adverse events (6, 12 and 24 months after study treatment).

    Time frame: 6, 12 and 24 months after study treatment

  3. Cosmetic outcome

    The cosmetic outcome is assessed based on photographs 6, 12 and 24 months after study treatment by descriptive statistics (an independent expert, the physician in charge and the patient assess the cosmetic outcome).

    Time frame: 6, 12 and 24 months after study treatment

07

Study locations

12 sites
  • Universitätsklinik für Frauenheilkunde, Allgemeines Krankenhaus der Stadt Wien
    Vienna, 1090, Austria
  • Vivantes Klinikum Am Urban
    Berlin, 10967, Germany
  • DRK Kliniken Westend
    Berlin, 14050, Germany
  • Universitätsklinikum Bonn
    Bonn, 53127, Germany
  • Kliniken Essen Mitte; Evang. Huyssens-Stiftung
    Essen, 45136, Germany
  • Agaplesion Markus Krankenhaus
    Frankfurt, 60431, Germany
  • Universitätsmedizin Greifswald
    Greifswald, 17475, Germany
  • Universitätsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • Rotkreuzklinikum München
    Munich, 80637, Germany
  • Klinikum rechts der Isar der Technischen Universität München
    Munich, 81675, Germany
  • Universitätsklinikum Ulm
    Ulm, 89075, Germany
  • GRN Klinik Weinheim
    Weinheim, Germany
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Jun 2022, 35 months.

Of 189 industry-sponsored observational studies under Breast Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 70. This study's 35 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2019
First posted
Mar 11, 2019
StartActual
Jul 4, 2019
Primary completionActual
Jun 22, 2022
CompletionActual
Nov 15, 2023
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03868514
Lead sponsor
pfm medical gmbh
Responsible party
Sponsor
First posted
Mar 11, 2019
Start date
Jul 4, 2019
Primary completion
Jun 22, 2022
Completion
Nov 15, 2023
Last update
Nov 18, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion